Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Description
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients¹, yet harbours mutation-derived T cell neoantigens that are suitable for vaccines ^(2,3). Here in a phase I trial of adjuvant autogene cevumeran, an individualized neoantigen
